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E-mail address: evans@salk.edu (R.M. Evans).Peroxisome proliferator-activated receptor gamma (PPARc), a ligand-regulated nuclear hormone
receptor, plays critical roles in metabolism and adipogenesis. PPARc ligands such as thiazolidined-
iones (TZDs) exert insulin sensitizing and anti-inﬂammatory effects primarily through action on adi-
pocytes, and are thus widely used to treat metabolic syndrome, especially type II diabetes. A number
of PPARc interacting partners have been identiﬁed, many of which are known epigenetic regulators,
including enzymes for histone acetylation/deacetylation and histone methylation/demethylation.
However, their functional roles in the PPARc transcriptional pathway are not well deﬁned. Recent
advances in ChIP-based and deep sequencing technology are revealing previously underappreciated
epigenomic mechanisms and therapeutic potentials of this nuclear receptor pathway.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
PPARc, a member of the nuclear receptor superfamily, is a
ligand-regulated transcription factor that is a key metabolic regu-
lator. It forms a heterodimer with retinoid X receptors (RXRs)
and binds to a speciﬁc DR-1 motif (direct hexa-nucleotide repeats,
separated by a single nucleotide) of PPAR response elements
(PPREs). There are two splice variants, PPARc1, which shows rela-
tively ubiquitous expression, and PPARc2, whose expression is re-
stricted to mature adipocytes [1]. These variants are driven by
distinct promoters, but differ only in their N-terminal sequence
and have similar transcriptional activities [1,2]. It is well estab-
lished that PPARc is a master regulator of adipogenesis. PPARc tar-
gets hundreds, possibly thousands, of downstream genes in
adipocytes, and is the only known factor that is necessary and suf-
ﬁcient for induction of adipocyte differentiation [3,4]. The PPARc2
isoform is induced earlier and more strongly than PPARc1 during
adipogenesis. The receptor is also required for maintaining the
proper functions of differentiated adipocytes [5,6]. While PPARc
is most highly expressed in adipocytes and adipose tissue, it is
present in numerous other cell types and tissues including macro-
phages, osteocytes, endothelial cells and placenta. PPARc in macro-
phages is implicated in anti-inﬂammation, uptake and reverse
transport of cholesterol, and subtype speciﬁcation [7,8]. The recep-chemical Societies. Published by Etor was shown to drive macrophage differentiation into the
alternatively activated, anti-inﬂammatory population (M2), rather
than the classically activated, proinﬂammatory population (M1)
[9]. PPARc inﬂuences distinct target genes in adipocytes versus
macrophages, but how these different genetic networks are estab-
lished is not well understood. It is likely that the network is in part
established by the distinctive chromatin pattern in each cell type
to produce broad patterns of eu- and hetero-chromatin. In addi-
tion, PPARc function is dependent on the availability of coregulator
proteins that modify chromatin states and as a result, may
differentially regulate the transcriptional activities of PPARc and
its target genes.
Many known coactivators and corepressors of PPARc and other
nuclear receptors have intrinsic histone modifying activities [10]. A
nucleosome, the fundamental unit of chromatin structure, consists
of two of each core histone, H2A, H2B, H3 and H4, and DNA
wrapped around the octameric core. The H3 and H4 histones
possess N-terminal tails protruding from the nucleosome, and
are particularly susceptible to post-translational modiﬁcations by
speciﬁc enzymes. Modiﬁcations of chromatin, such as histone acet-
ylation, methylation and phosphorylation, are important mecha-
nisms of epigenetic regulation. It is thought that combinations of
these modiﬁcations alter the local chromatin structure or physical
properties of histone tails, which can facilitate or block the tran-
scriptional machinery to bind to the promoter and initiate its activ-
ities. Whereas histone acetylation and phosphorylation may use
charge neutralization to affect chromatin structure, this may notlsevier B.V. All rights reserved.
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some of the modiﬁcations are merely a read-out of activities rather
than a primary mediator. In addition, it was demonstrated that a
number of these enzymes can modify not only histones but non-
histone proteins to inﬂuence transcription [10]. Furthermore,
direct methylation of DNA, usually at CpG dinucleotides, and
transcriptional modulation by small non-coding RNA are often
considered additional epigenetic mechanisms. Epigenetic enzymes
that are known to play pivotal transcriptional roles include histone
methyltransferases (HMTs), histone demethylases (HDMs), histone
acetyltransferases (HATs), histone deacetylases (HDACs), DNA
methyltransferases and DNA demethylases. For example, di- and
tri-methylation of lysine 9 or 27 of H3 (designated H3K9me2,
H3K9me3, H3K27me2 or H3K27me3) are considered repressive
chromatin marks, whereas mono-methylation of either lysine of
H3 or lysine 20 of H4 (H3K9me1, H3K27me1, or H4K20me1) and
acetylation of lysine 9 (H3K9ac) are marks of active chromatin
[10,11]. Histone acetylation exempliﬁed by H3K9ac facilitates the
access of RNA polymerase II to promoter regions just upstream of
transcriptional start sites and thus stimulates transcription [11].
It is reasonably expected that like other transcription factors,
epigenetic regulators underlie many activities of the nuclear recep-
tor superfamily including PPARc. Therefore, studying epigenetic
control by PPARc is key to understanding ligand-mediated tran-
scriptional regulation of metabolic pathways. However, few stud-
ies have investigated the speciﬁc contribution and association of
epigenetics changes that might be directed by this receptor. Recent
technical advances involving chromatin immunoprecipitation
(ChIP) such as ChIP–chip, ChIP–PET and ChIP–Seq now make it
possible to uncover potential epigenomic processes that regulate
or are regulated by PPARc under different conditions. Here we
review the current understanding of PPARc biology in the context
of epigenetics and present its perspectives in novel therapeutic ap-
proaches against metabolic disorders.
2. PPARc in metabolic diseases
Thiazolidinediones (TZDs), a class of drugs that act as insulin
sensitizers, are high afﬁnity ligands for PPARc [12]. Rosiglitazone
and pioglitazone, are the most common anti-diabetic TZDs used
clinically. While systemic, TZD treatment is effective in reducing
circulating glucose, insulin, triglyceride and free fatty acid levels
in diabetic subjects, although the molecular basis of this effect is
incompletely understood [13]. In order to gain insight into the site
and mechanism of action of the insulin-sensitizing pathway, vari-
ous tissue-speciﬁc knockout models of PPARc were created, over-
coming the obstacle of embryonic lethality in the whole body
knockouts [3]. Major tissues or cell types that affect systemic glu-
cose homeostasis include pancreas (e.g. b cells), muscle, liver
(hepatocytes) and adipose tissue (adipocytes and macrophages).
Deletion of PPARc in adipose tissue leads to insulin resistance in
mice fed a high fat diet [14,15]. On the other hand, muscle-speciﬁc
PPARc knockout mice develop insulin resistance under a normal
chow diet [16,17]. Macrophage-restricted deletion of PPARc also
results in systemic insulin resistance and glucose intolerance
[9,18]. In contrast, absence of PPARc in hepatocytes or b cells con-
fers only mild effects on whole body glucose metabolism [19,20].
While these studies suggested that adipose and non-adipose
PPARc contribute to insulin resistance, it remains unclear how
and where TZDs act as insulin sensitizers in the diabetic condition.
Pparg expression in non-adipose tissues is generally very low. It
was reported, however, that when adipose PPARc is deleted, com-
pensation occurs by increased gene expression in muscle and liver,
further complicating the use of tissue-speciﬁc knockouts to delin-
eate the site of the TZD action [21,22]. To avoid these complica-tions, we created gain-of-function PPARc models where the
receptor is constitutively activated through the fusion of a VP16
transactivation domain controlled by tissue-speciﬁc promoters
[6]. These animals allowed us to study the contribution of PPARc
in individual tissues or cell types under diet-induced insulin resis-
tant states. Unexpectedly, we found that selective activation of
PPARc in adipocytes is sufﬁcient to improve whole body insulin
resistance to a degree similar to systemic TZD treatment. Adipo-
cyte-speciﬁc PPARc activation leads to improved adipokine and li-
pid proﬁles, lowered serum insulin levels, and suppression of
macrophage inﬂammatory responses in a paracrine manner. These
results support an ‘‘adipocentric’’ model in which adipose activa-
tion of PPARc accounts for the systemic insulin sensitizing effect
of TZDs in the diabetic state. Consistent with this idea, the non-
TZD compound AG035029 exhibits more adipose-selective and
greater insulin sensitizing effects on Zucker fatty rats than any
other drugs tested, including TZDs such as pioglitazone, rosiglitaz-
one and troglitazone [6]. TZDs are known to have adverse side ef-
fects of osteoporosis, edema and heart failure, presumably by
activating PPARc in other cell types such as osteoclasts, collecting
duct cells and cardiomyocytes, respectively [23–26]. By developing
fat-speciﬁc PPARc modulators, it should be possible to lower the
risk of side effects while achieving maximum efﬁcacy in diabetic
therapy.
3. Transcriptional mechanisms of PPARc in adipocytes and
macrophages
PPARc binds to PPREs of its target gene promoters as a hetero-
dimer with RXR. It is generally believed that in the absence of li-
gands, PPARc associates with corepressor proteins including
SMRT and NCoR on PPREs. When agonists bind the receptor, these
corepressors are dissociated from the complex, and coactivator
proteins such as p300/CREB-binding protein (CBP) and SRC/p160
family proteins are recruited to the PPARc complex, resulting in
transcriptional activation. It was reported that this exchange of
corepressors and coactivators is mediated by TBL1 (transducin b-
like 1) and the related protein TBLR1 [27]. This suggests that the
transcriptional activities of PPARc are dynamic, yet highly coordi-
nated processes. However, the repertoire of its interacting partners
can be signiﬁcantly different from one cell type to another or from
one gene locus to another.
Pparg expression is high in adipocytes from both white adipose
tissue (WAT) and brown adipose tissue (BAT). White adipocytes
store energy primarily in the form of triglycerides and cholesterol
esters in a morphologically large lipid droplet, whereas brown adi-
pocytes contain abundant mitochondria, have more lobular fat
droplets and are specialized in burning energy. While PPARc is
critical in the development of both WAT and BAT in vivo [5,14],
many of its target genes are distinct at least in part due to the pres-
ence of different sets of interacting coregulators. Before full adipo-
genesis takes place in white adipocytes, corepressors such as NCoR
and SMRT are associated through their receptor-interacting do-
mains on PPARc2 and other speciﬁc target gene promoters and
maintain the repressive states of adipogenic genes [28,29]. In addi-
tion, it was reported that PPARc forms a repressive complex that
contains the retinoblastoma protein (pRb) and histone deacetylase
HDAC3 [30]. As HDAC3 is found in the complex with NCoR and
SMRT [31], the authors speculated that the presence of these core-
pressors facilitates pRb/HDAC3’s repressive activity, although this
hypothesis was not tested. Other corepressor proteins that are re-
ported to interact with PPARc and have repressive roles in adipo-
cytes are RIP140, SIRT1, TRB3 and TAZ (Fig. 1) [32]. During
differentiation into white adipocytes, phosphorylation of pRb dis-
lodges the pRb–HDAC3 repressive complex from the receptor
Fig. 1. Schematic representation of PPARc transcriptional cascades and chromatin
modiﬁcations in the repressive (upper diagram) and active (lower diagram) states
in adipocytes. Proteins shown in red are known to possess epigenetic enzyme
activities, and possibly affect methylation (me) and acetylation (ac) of histones
surrounding PPARc binding regions. Repressive histone marks shown to be
associated with PPARc include H3K9me2, H3K9me3, H3K27me2 and H3K27me3,
whereas activating marks include H3K4me2, H3K4me3, H4K20me1, H3K9ac and
H3K27ac. The repressed state is characterized by corepressor binding and repres-
sive methylation marks, whereas the activated state is indicated by coactivator
binding and active methylation and acetylation marks. The active state is also
characterized by PPARc agonist binding and C/EBP protein recruitment in proxim-
ity, leading to initiation of transcription by RNA polymerase II and general
transcription factors (GTFs). Some associations in the diagram need further
validating in vivo evidence and still remain hypothetical.
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ciate with PPARc and assist with its adipogenic activity. PPARc
activity also depends on components of a chromatin remodeling
SWI/SNF complex, ATPase BRG1 and BAF60c subunits [33]. Other
coactivators reported to be involved in PPARc-mediated adipogen-
esis are subunits of the Mediator complex (PBP/MED1/TRAP220
and MED14), CARM1 (coactivator-associated arginine methyl-
transferase 1), MEN1/Menin, CCPG (constitutive coactivator of
PPARc), ASC2/PRIP/NCOA6 and PTIP (Fig. 1) [32,34]. In addition
to PPARc, the CCAAT/enhancer binding protein (C/EBP) family of
transcription factors play an important role in adipogenesis. At
the initial phase of differentiation, C/EBPb and C/EBPd are induced
and stimulate expression of C/EBPa and PPARc. C/EBPa and PPARc
then act reciprocally to induce a number of adipogenic target genes
(e.g., aP2/FABP4, CD36, PEPCK, LPL, GLUT4 and adiponectin) and
sustain their own expression by a positive feedback loop, resulting
in terminal differentiation [13]. The majority of PPARc-binding
sites have been identiﬁed near C/EBPa-binding regions [35,36].
However, PPARc seems to be the principal driver of the adipogenic
program. Thus, while overexpression of PPARc can induce adipo-
genesis in C/EBPa-deﬁcient mouse embryonic ﬁbroblasts (MEFs),
exogenous C/EBPa expression is unable to do so in PPARc-deﬁcient
MEFs [13]. Accordingly, C/EBPa is most likely an associate factor
that helps establish a poised or ‘‘adipogenic’’ state by remodeling
chromatin but is dependent on PPARc to actually drive the
program.
Despite its essentiality, the contribution of PPARc to brown adi-
pocytes is less well understood. Also, C/EBPb appears to substitute
for C/EBPa, though the rationale for this is also not clear [37]. A
special feature of BAT is that its function of consuming or burning
fat to create heat is highly conditional. Induction of PPARc coacti-
vator-1 alpha (PGC-1a) is one key way to promote this process[38]. PGC-1a mRNA and protein levels are induced by beta-adren-
ergic stimulation triggered by cold exposure in BAT. In turn this in-
creases expression of mitochondrial oxidative metabolism and
adaptive thermogenic genes. One critical BAT-speciﬁc gene prod-
uct that helps to generate heat is UCP-1, which is activated by
PGC1a in a PPARc-dependent manner [13]. In contrast, PGC-1a
does not induce the classical PPARc target aP2/Fabp4 gene, indicat-
ing gene selective coactivator functions of PGC-1a. PGC-1a also
coactivates a number of other transcription factors including other
nuclear receptors such as PPARa, ERRa, ERRc, ERa and ERb [13].
Another BAT-speciﬁc transcription factor PRDM16 (PR domain
containing 16) was recently identiﬁed, and shown to bind PPARc
in a ligand-independent manner and enhance the PPARc transcrip-
tional activity [39]. Overexpression of PRDM16 in white preadipo-
cytes leads to induction of some brown adipogenic programs albeit
at lower levels of expression than in BAT itself. This ‘‘browning’’
may increase energy expenditure of WAT without actually con-
verting it to BAT. Other coregulators that are suggested to contrib-
ute to brown adipogenesis are RIP140, SRC-1, lipin-1 and CtBP1/2
(C-terminal binding protein 1 and 2) [32,40].
The macrophage PPARc program is also distinct from both adi-
pocyte populations. It was proposed that when TZD binds the
receptor in macrophages, a small fraction of PPARc is SUMOylated,
a modiﬁcation that converts the RXR:PPAR heterodimer to a mono-
mer, creating a novel interaction surface with the NCoR and SMRT
corepressor complex. This SUMOylated monomer then associates,
via a DNA binding independent process, to the promoters of
inﬂammatory genes to inhibit their transcriptional activity [8,41].
This active ‘‘transrepression’’ mechanism maintains a repressive
state of inﬂammatory transcription in a ligand-dependent manner
without involvement of classical PPREs. The SUMOylated PPARc–
NCoR complex has been shown to be recruited to AP1 sites through
interaction with c-Jun, and represses TLR4-inducible genes. How-
ever, the extent to which ligand-dependent repression is due to
this SUMOylated transrepression mechanism is not yet resolved.
Furthermore, indirect mechanisms such as induction of transcrip-
tional repressors or inhibitory micro-RNAs are likely. In regards
to direct ligand dependent effects, the ChIP-based whole genome
analysis shows that a majority of PPARc binding sites identiﬁed
in macrophages are classical DR-1 elements and adjacent to those
of C/EBPb and/or hematopoietic-speciﬁc transcription factor PU.1,
as opposed to C/EBPa in adipocytes [42]. While little is known
about the identity of PPARc-interacting partners associated on
the DR-1 sites in this cell type, the proximity with distinct tran-
scriptional machinery (i.e., PU.1) and possible differences in epige-
netic marks may be key determinants to achieve speciﬁcity of
macrophage target genes.4. Genome-wide studies of PPARc in adipocytes and
macrophages
Recent reports employing genome-wide ChIP analyses identi-
ﬁed the collection of cis-acting PPARc genomic targets (termed
‘‘cistrome’’) and suggested new aspects as to how chromatin
remodeling helps to direct both adipogenesis [35,36,43–46] and
macrophage activation [42]. Microarray-based platforms (ChIP-
on-chip [35,44,45]) and direct DNA sequencing-based methods
(ChIP-Seq [36,42,46], ChIP-PET [43]) have been used. As expected,
after adipocyte differentiation of 3T3-L1 cell lines, the vast major-
ity of PPARc binding sites overlap with those of its obligate hetero-
dimer RXRa. PPARc-binding regions are enriched in acetylation of
lysine 9 of H3 (H3K9ac) [35], consistent with the idea that receptor
binding correlates with active histone marks in mature adipocytes.
Importantly, a signiﬁcant proportion of PPARc binding regions are
shared by C/EBPa binding sites (>60%), the majority of which are
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other C/EBP family protein implicated in early adipogenesis, had a
proﬁle very similar to C/EBPa even in mature adipocytes, suggest-
ing possible redundancy of the two isoforms. The motif analyses of
surrounding sequences reveals that most of the PPARc DR-1 sites
are adjacent to C/EBP binding elements [36]. This suggests that
PPARc and C/EBP family proteins functionally cooperate, in the
context of short distances, to induce the adipogenic transcriptional
program (Fig. 1).
More recently, Mikkelsen et al. constructed genome-wide chro-
matin state and PPARc localization maps during adipogenesis [46].
Using murine 3T3-L1 cells and human adipose-derived mesenchy-
mal stem cells (ASCs) as models, they presented the extensive list
of preadipocyte- and mature adipocyte-speciﬁc cis-regulatory ele-
ments. Transcriptionally active histone marks H3K4me2/me3 and
H3K27ac were enriched near Ppargl and Pparg2 promoters in adi-
pocytes from both species, while repressive H3K27me3 was not.
H3K36me3, which is associated with transcriptional elongation,
was increased throughout the Pparg loci during adipogenesis.
PPARc-binding sites were also mapped genome-wide and localized
largely to distal regions enriched for the open chromatin mark
H3K27ac [46]. Although those overlapping in both models were
likely to have their genes upregulated, the majority of PPARc-bind-
ing regions were not shared between 3T3-L1 and hASCs (total of
approximately 7000 and 40000 sites, respectively). It was rea-
soned that this discrepancy is due to genetic divergence between
mouse and human. However, it is worth noting that the cell lines
they used are derived from different tissues and ages. Therefore,
their cell identities are likely to be different, and mechanisms of
adipogenic differentiation and phenotypes of mature adipocytes
may not be similar. Within adult adipose tissue, at least two pop-
ulations of cell types are capable of becoming mature adipocytes–
preadipocytes and ASCs [47]. 3T3-L1 cells are a derivative line orig-
inally subcloned from embryonic ﬁbroblasts. While it is not clear
whether 3T3-L1 cells are identical or close to the preadipocyte
lineage, this line is widely considered to be the best representative
of this cell type. ASCs are multipotent and can be differentiated
into mesodermal cell types, osteoblasts and chondrocytes, in addi-
tion to adipocytes, whereas preadipocytes are committed to be-
come adipocytes. Furthermore, compared to preadipocytes, ASCs
can be more effectively ‘transformed’ to induced pluripotent stem
cells (iPSCs) by introducing pluripotency-reprogramming factors
[48]. It will be of interest to study genome-wide epigenomic
changes at PPARc target gene loci in adipocytes, preadipocytes,
ASCs and iPSCs to delineate molecular signatures and mechanisms
that correspond to cell-speciﬁc PPARc activity states.
One study investigated the cistrome of PPARc in a non-adipo-
genic cell type, thioglycollate-activated peritoneal macrophages,
and compared these results to that found in adipocytes [42]. As
was the case for adipocytes, PPARc-speciﬁc DR-1 elements are
found in the majority (>75%) of identiﬁed binding sites in macro-
phages. Surprisingly, however, only 4% of PPARc binding regions
in adipocytes are also shared in macrophages. It was demonstrated
that macrophage PPARc colocalizes with PU.1, a hematopoietic
transcription factor that is required for monocyte development
and is not present in adipocytes. In addition, PPARc binding re-
gions are also adjacent to those of C/EBPb. Whether C/EBPa also
shares C/EBPb binding sites was not addressed. Macrophage-un-
ique PPARc regions show increased repressive histone marks,
H3K9me2 and H3K27me3, in adipocytes. In contrast, these regions
exhibit open chromatin states and increased active histone mark
H3K9ac in macrophages [42]. These data implicate that cell type
speciﬁcity of cistromes is achieved by unique transcriptional com-
ponents and distinct epigenetic regulation. Collectively, ChIP-
based cistromic studies revealed that proximity of PPARc binding
sites to C/EBP and PU.1 response elements helps to establish themacrophage speciﬁc PPARc response network. However, many
questions remain such as, what other proteins including coactiva-
tors, corepressors and transcription factors are involved in deter-
mining cellular speciﬁcity in addition to C/EBPs and PU.1? How
do epigenetic changes and chromatin remodeling contribute to
the transcriptional activities of PPARc in adipogenesis and inﬂam-
mation? The effect of PPARc ligands on the unliganded cistromes
in adipocytes and macrophages is also not clear. More extensive
cistromic analyses investigating other proteins and enzymes are
likely to answer some of these questions.5. Potential epigenetic players in PPARc signaling
Speciﬁc chromatin and DNA modiﬁcations that affect the PPARc
transcriptional pathway are considered in detail below. The his-
tone modifying enzymes and their possible functions described
in the text are listed in Table 1.
5.1. Histone acetyltransferases (HATs)
While we have limited knowledge about the effect of histone
acetylation and deacetylation on PPARc transcriptional activity,
several relevant enzymes are reported to regulate this pathway.
Two classes of common PPARc interacting coactivators, SRC/p160
family proteins and p300/CBP, are known to possess intrinsic
HAT activities. SRC family coactivators shown to interact with
PPARc are SRC-1, GRIP1/TIF2 (SRC-2) and ACTR/AIB1 (SRC-3).
While in vitro differentiation experiments point to important con-
tributions for each SRC in adipogenesis, studies using knockout
mice suggest much wider roles of each isoform in controlling en-
ergy balance between BAT and WAT in vivo [49–51]. Upon ligand
binding, PPARc undergoes conformational changes which provide
a contact site for LXXLL motifs in p300/CBP and SRC-1 and other
co-activators, through ‘charge clamp’ in its ligand binding domain
(LBD) [52]. In addition to ligand induced binding, p300/CBP pro-
teins can interact with the N-terminal AF-1 domain of PPARc in a
ligand-independent fashion [53]. Homozygous deletion of either
p300 or CBP is embryonic lethal. Although p300 and CBP are indis-
pensable for adipogenesis in vitro, their roles in vivo are not clear.
Studies in CBP heterozygotes imply a WAT-speciﬁc function of CBP
as this tissue shows signiﬁcant reduction in weight in these ani-
mals [54]. Very recently, it was found that at the initial stage of adi-
pogenesis another nuclear receptor, glucocorticoid receptor (GR), is
transiently recruited along with C/EBPb to a complex consisting of
PBP/MED1/TRAP220 and p300 to enhancer regions of Pparg2 iso-
form [55]. In response to glucocortocoids, this results in a transient
increase in H3K9 acetylation and enhances the induction of
PPARc2, which becomes the principal driver of adipogenesis. Cy-
clin D1 was shown to physically interact with p300 where it inhib-
its HAT activity and thus represses PPARc activity [56]. PGC-1a
activation of PPARc also enhances interactions with SRC-1 or
p300/CBP both in vitro and in vivo [57]. However, how HAT activ-
ities of the SRC and p300 family proteins contribute to the PPARc
transcriptional program remains obscure. It is presumed that
recruitment of these proteins promotes histone acetylation near
transcriptional start sites, allowing the RNA polymerase to initiate
transcription. As was described earlier, increased H3K9ac marks
were found to increase at PPARc binding sites during adipogenesis
[35,58]. It would be important to test if the enzymatic activities of
SRC or p300 coactivators are correlated with histone acetylation.
Other acetylation-dependent mechanisms are also possible. One
possibility is that SRC or p300 family members can directly acety-
late other interacting proteins in a complex or even PPARc itself.
Such non-histone acetylation may induce their conformational
changes and alter protein functions, as was demonstrated for other
Table 1
Epigenetic enzymes involved in PPARc transcription.
Enzyme Histone substratea Cofactors or TFs affecting PPARc Effectsb
Histone acetyltransferases (HATs)
SRC-1 H3, H4 PGC-1a Ligand-dependent PPARc coactivation
p300/CBP H2A, H2B, H3, H4 (i) Cyclin D1; (ii) PGC-1a; (iii) GR, C/EBPb, MED1 (i) Inhibits PPARc activity; (ii) PPARc coactivation; (iii) increases
Pparg2 expression
Histone deacetylases (HDACs)
HDAC1 H2A, H2B, H3, H4 Cyclin D1, HDAC3, SUV39H1 Inhibits PPARc activity
HDAC3 H2A, H2B, H3, H4 (i) pRb, NCoR, SMRT; (ii) IjBa;
(iii) NCoR, c-Jun; (iv) Adipose/ADP
(i) Corepresses PPARc; (ii) TNFa-mediated inhibition of PPARc
activity; (iii) ligand- and SUMOylation-dependent PPARc
transrepression in macrophages; (iv) inhibits PPARc activity
SIRT1 H3K9, H4K16? NCoR, SMRT Corepresses PPARc activity
Histone methyltransferases (HMTs)
SETDB1 H3K9 Wnt5a, NLK, CHD7 Corepresses PPARc activity
SETD8/Set7 H4K20 ? Induced by PPARc; coactivates Pparg and target gene expression
SUV39H1 H3K9 Cyclin D1, HDAC1, HDAC3 Inhibits PPARc activity
MLL3/MLL4 H3K4 (i) ASC-2/PRIP/NCOA6; (ii) PTIP (i) Ligand-dependent PPARc/RXRa coactivation; (ii) increases
Pparg and Cebpa expression
MLL1/MLL2 H3K4 MEN1/menin Coactivates PPARc activity
? H3K9 MeCP2, HP1a HP1a-dependent corepression of Pparg expression in HSCs
EZH2 H3K27 MeCP2 Induced by MeCP2; represses Pparg expression in HSCs
CARM1 H3R2, H3R17, H3R26 ? Ligand-dependent PPARc coactivation of aP2 gene
PRMT2 H4? ? Interacts with PPARc; coactivates PPARc activity?
Histone demethylases (HDMs)
JHDM2A H3K9 PGC-1a, p300/CBP, SRC-1 Coactivates PPARc/RXRa in b-adrenergic induction of UCP1 gene
UTX H3K27 ASC-2/PRIP, MLL3, MLL4 Counteracts with HMT activities?
TF: transcription factor.
a These do not necessarily affect PPARc activity; other substrates (histones or non-histones) are possible.
b Unless noted, these effects are in adipocytes.
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capable of acetylating androgen receptor (AR) and estrogen recep-
tor alpha (ERa), to control both transcriptional activity and ligand
sensitivity [59,60].
5.2. Histone deacetylases (HDACs)
In contrast to the gene activating functions of HATs, HDACs are
known to repress gene expression by deacetylating histones and
condensing chromatin, thereby making the regions inaccessible
to the transcriptional machinery. The 18 known human HDACs
are classiﬁed by sequence and domain organization into four clas-
ses, class I (HDAC1, -2, -3 and -8), class IIa (HDAC4, -5, -7 and -9),
class IIb (HDAC6 and -10), class III (sirtuin family including SIRT1
through -7) and class IV (HDAC11). Various HDAC inhibitors are
effective in causing cell cycle arrest, differentiation and apoptosis
of tumor cells in vivo, and thus considered promising candidates
for cancer therapy [61]. Several HDACs, notably HDAC1, -2, -3
and -5, are signiﬁcantly downregulated during adipogenesis
in vitro [62]. However, there are conﬂicting results regarding the
effects of knocking down HDACs on adipogenesis [62,63]. For
example, treatment with HDAC inhibitors such as valproic acid
and trichostatin A, reduces PPARc levels and blocks adipogenesis
in 3T3-L1 cells [64]. Cyclin D1 inhibits PPARc-dependent transcrip-
tion and adipogenesis. It was reported that cyclin D1 recruits
HDAC1, HDAC3 and histone methyltransferase SUV39H1 to PPREs,
decreases total H3 or H3K9 acetylation, and thus inhibits the
PPARc activity [65]. As described above, HDAC3 associates with
pRb as a PPARc repressive complex, leading to inhibition of adipo-
cyte differentiation, which is reversed by phosphorylation of pRb
[30]. TNFa also is known to block PPARc function. It appears that
IjBa-dependent nuclear translocation of HDAC3 accounts for the
inhibitory action of TNFa [66]. In addition, HDAC3 mediates the
transrepression mechanism of PPARc in macrophages by associat-
ing with the NCoR complex on inﬂammatory gene promoters in a
SUMOylation-dependent manner as discussed above [41]. Adipose
(ADP) protein represses adipogenesis by inhibiting PPARc tran-scriptional activity [67]. It was found that ADP associates with his-
tones and HDAC3, implicating a potential chromatin modiﬁcation
role for ADP. Consistent with this idea, inhibition of HDAC activi-
ties effectively reverses ADP-mediated blockage of adipogenesis
[67].
Among seven mammalian sirtuins, class III NAD-dependent
HDACs, SIRT1 plays an essential role in stress resistance and calorie
restriction-related extension of lifespan (in yeast and worms), and
thus has been most extensively studied. It was reported that SIRT1
is expressed in WAT and represses Pparg [68]. SIRT1 overexpres-
sion blocks adipogenesis, whereas inhibition of the endogenous
protein increases it in vitro in 3T3-L1 cells. In vivo, fasting induces
SIRT1 to bind to PPARc binding sites of fat-speciﬁc genes along
with corepressors NCoR and SMRT, enhancing repressive functions.
As a result, SIRT1 mediates fasting-induced lipolysis of triglycer-
ides into free fatty acids, which is compromised in heterozygous
SIRT1 mutant animals [68]. It was demonstrated more recently
that a subset of PPARc target genes, including Ero1-La, FGF21,
SCD3 and ELOVL3, but not classical targets, such as aP2, adiponec-
tin and C/EBPa, are repressed by SIRT1 in vitro [69]. Activation of
these genes was observed by inhibition of SIRT1, to a degree sim-
ilar to TZD treatment. How SIRT1 acquires binding speciﬁcity to
this subgroup of PPARc targets remains to be determined.
5.3. Histone methyltransferases (HMTs)
Histone methylation on lysine or arginine residues also plays a
key role in regulating transcriptional activities. In contrast to his-
tone acetylation that is mostly indicative of activation marks,
methylation marks are associated with both active and inactive
transcription. Modiﬁcations at speciﬁc residues of histones and
most likely combinations of these changes determine active or
repressive status of gene expression. The ﬁnding that macro-
phage-speciﬁc PPARc regions exhibit dramatically increased
repressive marks H3K9me2 and H3K27me3 in adipocytes indicates
the importance of histone methylation in achieving cell speciﬁcity
of its target gene expression [42]. The best-studied HMTs for
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DB1 (SET domain bifurcated 1) and SETD8/PR-Set7 (PR/SET do-
main-containing protein 7). SETDB1 forms a corepressor complex
that includes NLK (Nemo-like kinase) and represses PPARc trans-
activation via H3K9 methylation [45,70]. Wnt-5a, a known inhibi-
tory factor of adipogenesis, activates NLK, which phosphorylates
SETDB1. This leads to formation of the corepressor complex and
inhibits adipogenesis, which in turn promotes osteogenesis of mul-
tipotent mesenchymal stem cells [70]. ChIP–chip experiments
identiﬁed signiﬁcant PPARc binding to 10 of over 45 SET domain
family genes [45]. Among these, SETDB1 and SETD5 are downreg-
ulated during adipogenesis, and knockdown of SETDB1 enhances
differentiation of 3T3-L1 cells. In contrast, SETD8 is a direct target
of PPARc, is induced during adipocyte differentiation, and its
knockdown leads to inhibition of adipogenesis [45]. Importantly,
SETD8 mono-methylates H4K20, and regulates PPARc-dependent
activation of many target genes during adipogenesis through an in-
crease in H4K20 monomethylation. Thus, H4K20me1 is a novel
epigenetic mark for adipogenesis at least in vitro. SUV39H1 is an-
other SET domain family protein and as described earlier, it coop-
erates with deacetylases, HDAC1 and HDAC3 in cyclin D1-
mediated inhibition of PPARc-dependent adipogenesis, although
its exact repressive function as a HMT is not clear [65].
MLL3 and MLL4, H3K4 methyltransferases, form a complex
including the ASC-2/PRIP/NCOA6 protein, termed ASCOM (ASC-2
complex). ASC-2 is known to play an essential role in adipogenesis
directed by PPARc. Using knockout models, both MLL3 and MLL4
proteins were demonstrated to play redundant but critical roles
in PPARc-dependent adipogenesis in vitro and in vivo [71]. MLL3
and MLL4 interact with PPARc/RXRa in a TZD ligand-dependent
manner, tri-methylate H3K4 at the aP2 promoter, and concomi-
tantly increase H3 and H4 acetylation, possibly through the HAT
activity of p300/CBP. PTIP (Pax transactivation domain-interacting
protein) is also capable of forming a complex with ASC2–MLL3–
MLL4 and modulating HMT activity. PTIP is required for expression
of Pparg and Cebpa by increasing the active mark H3K4me3 on
these promoters [72]. Consequently, PTIP was shown to be essen-
tial for adipogenesis both in vitro and in vivo. Other members of
H3K4 methyltransferases, MLL1 and MLL2, establish an integral
complex with the MEN1/menin tumor suppressor, whose human
mutations are associated with various tumors including lipomas.
It was demonstrated that MEN1 interacts with PPARc, enhances
its target gene expression through increased H3K4 trimethylation,
and is required for adiopgenesis [73]. Hepatic stellate cells (HSCs)
undergo myoﬁbroblastic transdifferentiation by suppressing the
PPARc-dependent adipogenic program. Recent studies showed
that methyl-CpG binding protein 2 (MeCP2) is recruited to Pparg
promoter along with transcriptional repressor heterochromatin
protein 1 alpha (HP1a), and increases its H3K9 methylation in
HSCs [74,75]. It is not certain which HMT is responsible for
HP1a-mediated H3K9 methylation. MeCP2 also stimulates expres-
sion of HMT EZH2 and enhances H3K27 methylation in HSCs,
further remodeling chromatin into the repressive structure sur-
rounding Pparg.
In contrast to lysine methylation, very little is known about the
potential role of arginine methylation in adipogenesis. Protein argi-
nine methyltransferases (PRMTs) are comprised of 10 members
(PRMT1 through -9 and FBXO11). PRMTs can methylate a diverse
group of transcription factors and coregulators as well as histones
[76]. PRMT4/CARM1 was originally identiﬁed as a binding partner
for the p160/SRC protein GRIP1/TIF2/SRC-2 and acts as a coactiva-
tor for several nuclear receptors. In addition to H3 histone at H3R2,
H3R17 and H3R26, CARM1 also methylates other coactivators,
p300/CBP and SRC-3, indirectly affecting the activities of these
HATs [76]. Only one study has investigated the role of PRMTs, spe-
ciﬁcally CARM1, in the PPARc pathway [77]. CARM1 was found toassociate with PPARc on the aP2 promoter, and enhance transcrip-
tional activity of the receptor in a ligand-dependent manner.
CARM1 knockdown blocks adipogenesis in vitro, and CARM1-null
embryos exhibit reduced BAT [77]. Although CARM1 recruitment
is coincident with increased H3R17 methylation at the aP2 pro-
moter, it is not yet clear how CARM1 augments PPARc activity
and adipogenesis. For example, CARM1 has been shown to mey-
thylate the nuclear receptor co-factor CBP and might thus act inde-
pendently of histone modiﬁcation. In addition to CARM1, PRMT2
was reported to interact with PPARc as well as other nuclear recep-
tors, but its function is unknown [78]. The observation that PRMT2
coactivates the transcriptional activity of ERa predicts that this
may also be the case for PPARc.
5.4. Histone demethylases (HDMs)
Direct evidence for HDMs to participate in the PPARc pathway
is scarce as well. One report investigated the function of H3K9-spe-
ciﬁc HDM, JHDM2A (a.k.a. JMJD1A/KDM3A), by knocking out this
protein [79]. JHDM2A is highly expressed in BAT, and animals lack-
ing the protein have defects in b-adrenergic responses in BAT and
display obesity and dyslipidemia. Upon b-adrenergic stimulation,
JHDM2A is recruited along with PPARc, RXRa, PGC-1a, p300/CBP
and SRC-1 to the PPRE of UCP1 gene, and reduces H3K9me2 levels
at the PPRE [79]. This result unveils dynamic involvement of the
HDM in a coactivator complex-mediated metabolic gene regula-
tion. The HMT PTIP–ASC2–MLL3–MLL4 complex, which was de-
scribed earlier, also contains UTX, a H3K27 demethylase, though
the functional signiﬁcance for its presence in the complex is un-
known [72]. It is possible that many HMT complexes also possess
components with counteracting HDM activities. Important roles
of HDMs in other nuclear receptors have been noted. For example,
LSD1/KDM1 associates with and is important for transcriptional
activation of androgen receptor and ERa target genes by demethy-
lating H3K9 [80,81]. Similar mechanisms may exist for the PPARc
cascade.
5.5. DNA methylation
DNA methylation is the only known regulatory modiﬁcation of
DNA itself, and involves addition of a methyl group to the carbon-5
position of cytosine typically in CpG dinucleotides. Although it is
associated with gene silencing it is believed that this is dependent
on the recruitment of relevant repressive complexes. DNA methyl-
ation is catalyzed by DNA methyltransferases (DNMTs). As with
HDAC inhibitors, DNMT inhibitors (such as 5-aza-cytidine) have at-
tracted great interest as epigenetic therapeutic agents for cancer
[82,83]. 5-Azacytidine is the ﬁrst epigenetic drug approved by
FDA and used for treatment of myelodysplastic syndrome. Combi-
nations of HDAC and DNMT inhibitors also appear to have syner-
gistic effects and are currently explored for treating acute
myeloid leukemia and other tumors. On the other hand, the iden-
tities of DNA demethylases have been controversial, although sev-
eral proteins have been proposed to possess such activities [82,83].
There have been no studies that clearly deﬁne the molecular mech-
anisms of DNA methylation in Pparg regulation. In the case of the
PPARc coactivator PGC-1a, it was demonstrated that DNMT3B is
involved in TNFa- or free fatty acid-induced hypermethylation at
non-CpG nucleotides and reduction of mitochondrial content in
skeletal muscle from diabetic subjects [84]. In one study, hypome-
thylation of adipogenic loci including those from Pparg2, Leptin,
aP2 and Lpl genes, was found in ASCs, which have a high adipo-
genic potential [85]. In contrast, myogenic or endothelial loci were
hypermethylated in ASCs, and adipogenic loci were more
methylated in non-adipogenic, hematopoietic cells. However, no
change in hypomethylation was observed after adipogenesis,
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a differentiation potential, but does not determine gene expression
for driving adipogenesis [85]. Nevertheless, another study reported
that the Pparg2 promoter is hypermethylated in the 3T3-L1 prea-
dipocyte model and that upon induction of differentiation the re-
gion is gradually demethylated [86]. Methyl CpG-speciﬁc binding
protein MeCP2 is associated with the promoter in preadipocytes,
but is dismissed after differentiation. PPARc expression is in-
creased in non-adipogenic NIH3T3 cells by treatment of the DNMT
inhibitor, 5-aza-cytidine. Moreover, increased methylation of the
Pparg2 promoter and concomitant reduction of its expression
was found in visceral WAT of obese animals [86]. As described
above, MeCP2 is recruited to the PPARc site, leading to HP1a-
dependent H3K9 methylation and EZH2-dependent H3K27 meth-
ylation to repress its expression in HSCs [74,75]. This result dem-
onstrates an epigenomic relay pathway, which connects DNA
methylation to histone methylation for gene regulation. Recently,
it has been shown that the Tet1 (Ten-eleven translocation) protein
can convert 5-methylytosine to 5-hydroxymethylcytosine (5hmc)
raising the possibility that this represents a new epigenetic mark
[82,83]. More work will be necessary to explore and delineate
additional roles of DNA methylation and associated enzymes in
transcriptional regulations of PPARc.
6. Conclusion and perspectives
Despite the powerful inﬂuences on gene expression and pheno-
type, studies to deﬁne epigenetic molecular players and mecha-
nisms in the PPARc signaling have just begun. Speciﬁc PPARc
agonists exhibit adipogenic, lipogenic, insulin sensitizing and
anti-inﬂammatory effects. It is thought that these properties orig-
inate from adipose tissue and account for the anti-diabetic action
of the TZD compounds in insulin resistance. However, TZDs cause
unwanted side effects, presumably by targeting non-adipose cell
types such as cardiomyocytes, collecting duct cells and osteoclasts.
Development of selective PPARc modulators or activators that are
speciﬁc to adipocytes should preserve the drug efﬁcacy while
reducing side effects. Another possible means to achieve adipose
selectivity could be a combination therapy of the existing TZDs
with epigenetic modulators. For example, by identifying HDAC or
DNMT inhibitors that are speciﬁcally effective in epigenetically
activating adipogenic gene promoters, it may be possible to com-
bine them with a lower dose of TZD yet achieve a strong anti-dia-
betic action. Anti-inﬂammatory aspects of the PPARc ligands may
also offer enhanced therapeutic power of existing epigenetic drugs
for cancer or inﬂammatory diseases when used in combination.
While use of HDAC and DNMT inhibitors has been successful in
cancer therapy and may be a promising target for metabolic dis-
eases, potential mechanisms of their action in metabolic pathways
are largely unknown. Identiﬁcation of additional molecular factors
that mediate the PPARc transcriptional pathway is likely to con-
tribute to our understanding and designing of future therapeutic
approaches in the metabolic disorders.
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